Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.55 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.52 |
| ▸ | APEX1 | P27695 | 1/20 | 0.51 |
| ▸ | METAP2 | P50579 | 1/20 | 0.51 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.51 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.51 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.51 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL920172 | 0.88 | HTT (0.57) | ADORA2AL3MBTL1HTTHPGDLMNA | |
| SCHEMBL1630899 | 0.85 | USP2 (0.60) | KMT2AHTTHPGDLMNAGAA | |
| Hydrochloric Acid SCHEMBL1875819 | 0.84 | USP2 (0.59) | KMT2AHTTHPGDLMNAGAA | |
| SCHEMBL5012093 | 0.82 | ADORA2A (0.47) | ADORA2AKMT2AL3MBTL1MEN1NPC1 | |
| SCHEMBL13070867 | 0.81 | ADORA2A (0.53) | ADORA2AKMT2AL3MBTL1MEN1NPC1 | |
| SCHEMBL920392 | 0.79 | NSD2 (0.66) | ADORA2AKMT2AL3MBTL1HPGDLMNA | |
| SCHEMBL4060965 | 0.78 | KMT2A (0.53) | KMT2AL3MBTL1MEN1NPC1HSP90AA1 | |
| SCHEMBL1680921 | 0.78 | ADORA2A (0.50) | ADORA2AKMT2AL3MBTL1MEN1NPC1 | |
| SCHEMBL921509 | 0.78 | HPGD (0.55) | ADORA2AL3MBTL1HTTHPGDLMNA | |
| SCHEMBL28449389 | 0.78 | SLC6A12 (0.44) | ADORA2AKMT2AMEN1SLC6A12HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2789338-A2 | Condensed pyridine derivate and use thereof | Takeda Pharmaceutical Company Limited (JP) | 2014-10-15 | — | — | EP | disclosed |
| EP-2789338-A2 | Condensed pyridine derivate and use thereof | Takeda Pharmaceutical Company Limited (JP) | 2014-10-15 | — | — | EP | disclosed |
| US-20100266504-A1 | CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-21 | — | — | US | disclosed |
| US-20100266504-A1 | CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-21 | — | — | US | disclosed |
| US-20100266504-A1 | CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-21 | — | — | US | disclosed |
| EP-2216023-A1 | CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2010-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100266504-A1 | CONDENSED PYRIDINE DERIVATIVE AND USE THEREOF | HTR2C, HTR5A, HTR3C | ADORA2A 279/4885KMT2A 3157/4885L3MBTL1 3184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.